HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.048082v1 49/5/694    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Terakawa, Y. Articles by Ohata, K. Search for Related Content PubMed PubMed Citation Articles by Terakawa, Y. Articles by Ohata, K.

Diagnostic Accuracy of ¹¹C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy

¹ Department of Neurosurgery, Graduate School of Medicine, Osaka City University, Osaka, Japan; ² Department of Neurosurgery, Osaka City General Hospital, Osaka, Japan; and ³ Department of Nuclear Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan

Correspondence: For correspondence or reprints contact: Yuzo Terakawa, Department of Neurosurgery, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail: terakawa{at}msic.med.osaka-cu.ac.jp

We evaluated the diagnostic accuracy of PET with L-methyl-¹¹C-methionine (¹¹C-MET) for the differentiation of recurrent brain tumors from radiation necrosis. Methods: Seventy-seven patients who had been previously treated with radiotherapy after primary treatment for metastatic brain tumor (n = 51) or glioma (n = 26) were studied to clarify the diagnostic performance of ¹¹C-MET PET in differentiating between recurrent brain tumors and radiation necrosis. A total of 88 PET scans with ¹¹C-MET were obtained; sometimes more than one scan was obtained when there was an indication of recurrent brain tumor or radiation necrosis. A definitive diagnosis was made on the basis of pathologic examination for recurrent brain tumors and on the basis of pathologic examination or clinical course for radiation necrosis. Several indices characterizing the lesions were determined; these included mean and maximum standardized uptake values (SUV_mean and SUV_max, respectively) and the ratios of lesion uptake to contralateral normal frontal-lobe gray matter uptake corresponding to the SUV_mean and the SUV_max (L/N_mean and L/N_max, respectively). Receiver-operating-characteristic (ROC) curve analysis was used to determine the optimal index of ¹¹C-MET PET and cutoff values for the differential diagnosis of tumor recurrence and radiation necrosis. Results: The values of each index of ¹¹C-MET PET tended to be higher for tumor recurrence than for radiation necrosis. There were significant differences between tumor recurrence and radiation necrosis in all of the indices except for the L/N_max for glioma. ROC analysis indicated that the L/N_mean was the most informative index for differentiating between tumor recurrence and radiation necrosis. An L/N_mean of greater than 1.41 provided the best sensitivity and specificity for metastatic brain tumor (79% and 75%, respectively), and an L/N_mean of greater than 1.58 provided the best sensitivity and specificity for glioma (75% and 75%, respectively). Conclusion: ¹¹C-MET PET can provide quantitative values to aid in the differentiation of tumor recurrence from radiation necrosis, although these values do not appear to be absolute indicators. Quantitative analysis of ¹¹C-MET PET data may be helpful in managing irradiated brain tumors.

Key Words: ¹¹C-MET • PET • radiotherapy • radiation necrosis

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				T. Uda, N. Tsuyuguchi, Y. Terakawa, T. Takami, and K. Ohata Evaluation of the Accumulation of 11C-Methionine with Standardized Uptake Value in the Normal Brain J. Nucl. Med., February 1, 2010; 51(2): 219 - 222. [Abstract] [Full Text] [PDF]

				P.C. Sundgren MR Spectroscopy in Radiation Injury AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1469 - 1476. [Abstract] [Full Text] [PDF]

				M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]

				L.S. Hu, L.C. Baxter, K.A. Smith, B.G. Feuerstein, J.P. Karis, J.M. Eschbacher, S.W. Coons, P. Nakaji, R.F. Yeh, J. Debbins, et al. Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements AJNR Am. J. Neuroradiol., March 1, 2009; 30(3): 552 - 558. [Abstract] [Full Text] [PDF]

				E. A. Smith, R. C. Carlos, L. R. Junck, C. I. Tsien, A. Elias, and P. C. Sundgren Developing a Clinical Decision Model: MR Spectroscopy to Differentiate Between Recurrent Tumor and Radiation Change in Patients with New Contrast-Enhancing Lesions Am. J. Roentgenol., February 1, 2009; 192(2): W45 - W52. [Abstract] [Full Text] [PDF]

				G. A. Alexiou, S. Tsiouris, A. P. Kyritsis, K. S. Polyzoidis, and A. D. Fotopoulos Brain SPECT by 99mTc-Tetrofosmin for the Differentiation of Tumor Recurrence from Radiation Injury J. Nucl. Med., October 1, 2008; 49(10): 1733 - 1734. [Full Text] [PDF]

				Y. Terakawa and N. Tsuyuguchi Reply: Brain SPECT by 99mTc-Tetrofosmin for the Differentiation of Tumor Recurrence from Radiation Injury J. Nucl. Med., October 1, 2008; 49(10): 1734 - 1734. [Full Text] [PDF]